• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Abbott, American Diabetes Association Launches Therapeutic Nutrition Program for People with Diabetes

Share:

July 3, 2023

The American Diabetes Association (ADA) and Abbott have announced a collaboration to pilot a therapeutic nutrition program for people with Type 2 diabetes. Abbott is providing a $2.65 million grant over three years to support the initiative. The collaboration will explore how diabetes technology, specifically continuous glucose monitoring (CGM) systems, can help individuals with diabetes make informed decisions about their diet and activity. The program aims to leverage CGM data to understand how personalized therapeutic nutrition can assist people in achieving their diabetes management goals.

What You Should Know:

  • American Diabetes Association® (ADA) and Abbott announced a collaboration a new collaboration on a pilot therapeutic nutrition program to help people living with Type 2 diabetes.
  • The collaboration aims to understand how diabetes technology like continuous glucose monitoring (CGM) systems can help people living with diabetes make informed decisions about their food and activity.

Abbott’s $2.6M Grant to Support Diabetes

Abbott is providing a $2.65 million grant over the next three years to the ADA to enable them to:

  • Engage with top healthcare professionals and key opinion leaders to evaluate existing clinical evidence on the use of CGM systems for personalized, therapeutic nutrition.
  • Launch two pilot programs targeted at adults with Type 2 diabetes to gain a deeper understanding of the role a CGM can play in personalized therapeutic nutrition. These programs will leverage CGM data to understand how they help people with diabetes achieve their objectives, which include modifications to their nutritional intake and dietary habits.
  • Host roundtable discussions in collaboration with renowned health care experts to review and evaluate the existing clinical evidence. These discussions will investigate the role of therapeutic nutrition using CGM data and its potential to inform nutrition recommendations.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

“What people with diabetes eat is a critical part of managing their diabetes,” said Charles “Chuck” Henderson, chief executive officer of the ADA. “Personalized nutrition using CGMs has the potential to revolutionize diabetes management by providing individuals with more data and tools to manage their glucose levels, improve their quality of life, and reduce the risk of diabetes-related complications. The ADA is grateful to Abbott for its continued support of our mission to improve the lives of people impacted by diabetes. “

Source: HitConsultant

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Pressure BioSciences Pending Merger Partner Cannaworx, Inc. Announces Letter of Intent to Acquire Five Leaf Labs, Delivering Major Expansion of Sales and Distribution NetworkPressure BioSciences Pending Merger Partner Cannaworx, Inc. Announces Letter of Intent to Acquire Five Leaf Labs, Delivering Major Expansion of Sales and Distribution Network
  • Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel DiseaseRoche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease
  • Intersystems, Virtusa Partner on Patient Data Integration, AnalyticsIntersystems, Virtusa Partner on Patient Data Integration, Analytics
  • Janssen Taps Komodo Health to Optimize Site Selection and Patient Recruitment for Clinical TrialsJanssen Taps Komodo Health to Optimize Site Selection and Patient Recruitment for Clinical Trials
  • Apple & UCLA Kick Off Device-Driven Depression and Anxiety StudyApple & UCLA Kick Off Device-Driven Depression and Anxiety Study
  • Sanofi completes acquisition of KadmonSanofi completes acquisition of Kadmon
  • Labyrinthitis Market 2021 Industry Insights by Global ShareLabyrinthitis Market 2021 Industry Insights by Global Share
  • MJH Associates Inc. Acquires Medical Networking, Inc.; Strengthens Position in Healthcare IndustryMJH Associates Inc. Acquires Medical Networking, Inc.; Strengthens Position in Healthcare Industry

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications